Ablynx chairman pleased with sale to Sanofi: “For the benefit of everybody”
![Foto: /ritzau/Kåre Viemose](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article10186273.ece/ALTERNATES/schema-16_9/RITZAU_683921-(1).jpg)
This week, Belgian antibody company Ablynx accepted an DKK 29 billion (USD 4.82 billion) offer from French Sanofi that has then outpaced Novo Nordisk in the pursuit of the company.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.